Home

Treace Medical Concepts, Inc. - Common Stock (TMCI)

6.7200
+0.0600 (0.90%)
NASDAQ · Last Trade: Apr 26th, 2:30 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.660
Open6.580
Bid6.710
Ask6.720
Day's Range6.520 - 6.760
52 Week Range3.920 - 11.33
Volume422,883
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume370,434

Chart

About Treace Medical Concepts, Inc. - Common Stock (TMCI)

Treace Medical Concepts Inc is a medical technology company focused on developing and commercializing innovative solutions for foot and ankle surgery. The company specializes in advanced surgical techniques and devices aimed at improving patient outcomes, particularly in conditions such as bunions and other foot deformities. Treace Medical provides surgeons with minimally invasive products that enhance the precision and efficiency of surgical procedures, ultimately helping patients achieve quicker recovery times and improved mobility. Through ongoing research and development, Treace Medical strives to remain at the forefront of the orthopedic medical device industry. Read More

News & Press Releases

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 26, 2025
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 26, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · April 25, 2025
Treace to Report First Quarter 2025 Financial Results on May 8, 2025
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · April 24, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace Medical To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 23, 2025
Deadline Alert: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming June 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024, inclusive (the “Class Period”).
By Glancy Prongay & Murray LLP · Via Business Wire · April 22, 2025
Robbins LLP Reminds TMCI Stockholders With Large Losses to Contact the Firm for Information About the Class Action Against Treace Medical Concepts, Inc.
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.
By Robbins LLP · Via GlobeNewswire · April 21, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · April 21, 2025
Deadline Approaching: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming June 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024, inclusive (the “Class Period”).
By Law Offices of Howard G. Smith · Via Business Wire · April 21, 2025
TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · April 21, 2025
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI
NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 19, 2025
Law Offices of Frank R. Cruz Encourages Treace Medical Concepts, Inc. (TMCI) Investors To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024, inclusive (the “Class Period”). Treace Medical investors have until June 10, 2025 to file a lead plaintiff motion.
By Law Offices of Frank R. Cruz · Via Business Wire · April 18, 2025
TMCI Stockholder Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Treace Medical Concepts, Inc.
SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) --
By Robbins LLP · Via GlobeNewswire · April 17, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · April 17, 2025
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Treace Medical Concepts, Inc. (TMCI) Investors To Inquire About Securities Fraud Class Action
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024, inclusive (the “Class Period”). Treace Medical investors have until June 10, 2025 to file a lead plaintiff motion.
By Glancy Prongay & Murray LLP · Via Business Wire · April 17, 2025
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 17, 2025
ROSEN, LEADING INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 16, 2025
Law Offices of Howard G. Smith Encourages Treace Medical Concepts, Inc. (TMCI) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024, inclusive (the “Class Period”). Treace Medical investors have until June 10, 2025 to file a lead plaintiff motion.
By Law Offices of Howard G. Smith · Via Business Wire · April 16, 2025
TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) INVESTOR ALERT: Investors With Large Losses in Treace Medical Concepts, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · April 16, 2025
TMCI Investors Have the Opportunity to Lead the Treace Medical Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 16, 2025
Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024. Treace Medical describes itself as a “medical technology company focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.”
By The Rosen Law Firm, P.A. · Via Business Wire · April 15, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace Medical To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 11, 2025
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Treace Medical Concepts, Inc. (NASDAQ: TMCI)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b‑5) on behalf of all persons other than Defendants who purchased or otherwise acquired Treace Medical securities between May 8, 2023, and May 7, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: McCluney v. Treace Medical Concepts, Inc., et al., Case No. 3:25-cv-00390.
Treace Announces Upcoming Board Chair Transition
PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at the 2025 Annual Meeting of Stockholders, which is expected to occur on May 20, 2025. John T. Treace will continue to serve as Chief Executive Officer and will assume the role of Chairman of the Board immediately following the 2025 Annual Meeting of Stockholders. Richard W. Mott will continue to serve as the lead independent director.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · April 7, 2025
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · March 28, 2025